Mamotest is a social venture dedicated to increasing access to breast cancer early detection, diagnosis and patient guidance.
LeFil conducted a study on the positive externalities of Mamotest, creating a framework and quantitative model to estimate the economic benefits created by the venture not only for patients, but also other stakeholders such as the families of patients, employers and payers at large. It also computed the social return of investing into Mamotest.

